February 29, 2016 in Events
NWBioSpecimen conducted a survey to gauge the satisfaction of users during calendar year 2015. The survey results are now available.
3D microscopes may fundamentally change pathology and aid pathologists in the early detection/diagnosis of cancer as they may permit rapid biopsy interrogation by circumventing many standardized steps. This research which has received significant academic and media attention since 2014 is a collaborative/interdisciplinary project, where human biopsies provided by NWBioSpecimen are used in whole sample processing (“pathology-in-a-tube”), tissue transport and specimen optical clearing using our custom microfluidic device, benchtop experimental setups and 3D microscope.
UW Medicine’s Center for Cancer Innovation (CCI), founded by C. Anthony (Tony) Blau, M.D., published an article in the Journal of the National Comprehensive Cancer Network in January 2016 using research biospecimens prospectively procured by NWBioSpecimen.
Ellen Schur and Kenneth Maravilla’s research group in the UW Medicine Departments of General Internal Medicine and Epidemiology recently used Digital Pathology services at the Pathology Digital Imaging Core Facility to quantify glial fibrillary acidic protein (GFAP) staining in autopsy brain specimens.
A research collaboration between 10 National Institute on Aging AD Centers, led by principle investigator Thomas Montine (UW Medicine Department of Pathology), utilized digital pathology services at the UW Pathology Digital Imaging Core Facility to perform part of a multisite neuropathologic evaluation of AD cases.
May 05, 2015 in Events
NWBioSpecimen presented a poster at the 2015 ISBER Annual Meeting in Phoenix, Arizona, describing our approach to integrating and deploying a commercial biospecimen management software system into the informatics workflow of a comprehensive biobank.
September 03, 2014 in Events
NWBioSpecimen is co-hosting the Leaders in Biobanking Congress 2014 conference in Seattle, WA starting on September 14, 2014. Keynote topics include the business of biobanking and optimization of biospecimen use.
Dr. Anthony Blau extensively used NWSpecimen resources for prospectively collecting breast cancer biospecimens for analyzing the clonal composition of tumors. Dr. Blau’s lab preformed exome and deep sequencing on tumor subsections and developed algorithms that predict clonal relationships in breast cancer.
Dr. Stephen Schmechel collaborated with Dr. James McCarthy at the University of Minnesota to analyze hyaluronan pathway related members in intermediate-grade prostate cancer biospecimens.